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Introduction
The most common complications after pancreatoduodenectomy are delayed gastric-emptying, pancreatic leakage, and intra-abdominal abscess formation. 1 Hemorrhage following pancreaticoduodenectomy is less frequent; however, it is often a fatal complication. Hemorrhage can occur in the early or late postoperative phase. Hemorrhage within the first 24 hours after surgery is generally caused by a technical failure and needs immediate adequate hemostasis through a re-laparotomy. 1 Hemorrhage in the late postoperative phase may be secondary to peptic ulceration, ulceration at an anastomosis, dehiscence of an anastomotic suture line, or an injured intra-abdominal vessel. Infection or enzymatic leakage from anastomotic failure may result in arterial wall erosions and predispose to pseudoaneurysm formation. The ligated gastroduodenal artery stump and the common hepatic artery are the most frequently involved vessels. Late onset of bleeding, also termed delayed massive hemorrhage, presents as sudden or intermittent severe intra-abdominal bleeding. 1 Patients at this stage are often critically ill with postoperative and inflammatory adhesions making reoperation untenable. Endovascular arterial interventions include pseudoaneurysm embolization or exclusion via stent grafts. We present a case in which a coronary stent graft was used to emergently treat a ruptured replaced proper hepatic artery pseudoaneurysm in conjunction with trans-splenic portal vein stenting in the setting of post-pancreaticoduodenectomy hemorrhage with mass effect causing acute main portal vein occlusion.
Case Report
A 72-year-old man underwent pancreaticoduodenectomy complicated postoperatively by intra-abdominal abscess. He presented to the emergency room 7 weeks following surgery in hemorrhagic shock and acute liver failure. Pertinent laboratory values at presentation The occluded segment was traversed, and two overlapping Epic 12 × 40-mm self-expandable stents (Boston Scientific) were deployed. Repeat portography showed brisk flow into the portal system (►Fig. 3B). The trans-splenic access track was embolized with an 8-mm Nester coil (Cook Medical LLC).
The patient was discharged home after a prolonged intensive care unit (ICU) stay for pneumonia. Hepatic artery stent graft patency and portal stent patency were confirmed by contrast-enhanced CT 205 days after placement. Unfortunately, because of progressive tumor recurrence, the patient was placed in hospice and died soon thereafter.
Discussion
Delayed massive hemorrhage following pancreaticoduodenectomy carries a high mortality rate.
1 Several approaches to treat postoperative hemorrhage from pseudoaneurysms exist, including endovascular therapy, open repair, and conservative management. Lower mortality rates and decreased time in the intensive care unit have been reported in patients who undergo transarterial embolization and/or stent graft placement as compared with surgical repair. 2 Factors considered in treatment planning include the location, size and shape of the aneurysm, tortuosity and diameter of the involved vessels, and presence of collateral flow to involved organs. Patients with pancreaticoduodenectomy are noteworthy in that they no longer have a gastroduodenal artery to provide collateral perfusion following embolization because the artery is sacrificed at resection. Therapeutic embolization may stop exsanguinating bleeding but may also carry the disadvantage of excluding the distal circulation. This may cause liver ischemia and even fatal hepatic necrosis, particularly in patients with portal vein stenosis or thrombosis. 3 This was a factor in treatment planning for our patient. For patients in whom endovascular management is unsuccessful, a temporary balloon occlusion of the involved artery can serve as a lifesaving method until transfer to the operating room. Risk factors associated with poor outcome after endovascular therapy include preprocedural coagulopathy, portal vein stenosis, and absence of visualized flow through hepatic arteries. 4 The use of coronary stent grafts to exclude pseudoaneurysms is not frequently reported in the United States likely in part due to institutional review board (IRB) approval for use. Briguori et al demonstrated PTFE-covered coronary stents significantly reduce the necessity for emergency surgery compared with non-PTFE-covered stents for coronary perforations. 5 Muraoka and colleagues reported a case in which a coronary stent graft was used to exclude a bleeding hepatic artery pseudoaneurysm at the anastomotic site following liver transplantation. While the procedure was technically successful, the patient died from sepsis 8 days later. 6 Asai et al described treatment with a Jostent GraftMaster stent for delayed hemorrhage following pancreaticoduodenectomy for a common hepatic artery pseudoaneurysm on postoperative day 19 with stent patency seen at 9 months on CT. 3 The largest series was published by Wang et al, who reported their experience in nine patients with delayed massive hemorrhage from ruptured hepatic artery pseudoaneurysm after pancreaticoduodenectomy, using the same stent graft (Jostent, GraftMaster) for emergency vessel repair retaining patency of hepatic artery. Instead of coil embolization, stent graft was placed to exclude hepatic pseudoaneurysm because all patients had portal venous obstruction. 7 Six of nine patients survived with patent stents during a mean follow-up time of 10.5 months (range: 4-16 months). Our case is the only one to report stent graft placement in conjunction with reestablishing in-line portal flow.
While many stent grafts exist, the size of the vessels involved in the pancreatic bed may prevent use of the stent grafts that are designed for use in the periphery; iCAST (Atrium Medical Corporation), Viabahn, and Viabahn VBX (W. L. Gore & Associates, Inc), all of which have 5-mm-diameter stents as their smallest size. Furthermore, Viabahn is a self-expandable device on a 0.018-in platform with the shortest available length of 5 cm. Although the balloon-expandable devices have shorter stent lengths, they are on larger, less flexible 0.035-in platforms that may not allow for delivery of the stent graft in some visceral locations. In this case report, a PTFE-covered coronary stent was chosen to treat the proper hepatic pseudoaneurysm to preserve hepatic arterial flow given the patient's portal vein occlusion. Therapeutic embolization would not have been ideal in this instance because of the risk of hepatic necrosis. 1 Jostent/GraftMaster is a covered stent, ranging 2.8 to 4.8 mm in diameter and 16 to 26 mm in length. This stent was chosen because of its small diameter and short length, which was necessary for placement within the proper hepatic artery. Flexibility of the 0.014-in platform also allowed for delivery to an arterial segment after significant tortuosity. After the life-threatening hemorrhage was controlled, portal flow was reestablished with stent placement across the main portal vein to also help prevent hepatic necrosis.
In conclusion, this report describes lifesaving placement of a coronary stent graft for treatment of postoperative hepatic artery pseudoaneurysm in conjunction with portal vein stenting with documented patency at 205 days. GraftMaster RX is authorized by U.S. federal law for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels, or saphenous vein bypass grafts ≥ 2.75 mm in diameter. However, this stent is approved by the Food and Drug Administration (FDA) with a humanitarian device exemption and requires IRB auspices for use. Given our case and the other existing reports, its potential use in noncardiac life-threatening situations should be known.
